Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766322 · ClinicalTrials.gov registry record
Alcohol and Bariatric Surgery
A clinical trial, sponsored by University of Illinois at Urbana-Champaign.
- Terminated
- Registry status
- 54
- Enrollment target
NCT02766322: Clinical Trial study, sponsored by University of Illinois at Urbana-Champaign.
NCT02766322 is a clinical trial that was terminated before completion, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02766322 was terminated before completion, sponsored by University of Illinois at Urbana-Champaign.
- TERMINATED
- Registry status
- 54 participants
- Enrollment target
Study Summary
The investigators wish to study the effects of alcohol on three forms of bariatric surgery, Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG) and laparoscopic adjustable gastric banding (LAGB) and compare them with a non-surgical group. The surgery is not part of the clinical trial. If insurance does not cover the procedure, then the patient is responsible for payment of the surgical process. The investigators are doing pre and post surgery testing to provide a better understanding of the effect of bariatric surgery-induced weight loss on 1) alcohol absorption, distribution and elimination from the body, 2) the effects of alcohol on mood, and 3) the effects of alcohol on driving.
Primary Outcome
Time to reach peak blood alcohol levels and height of blood alcohol levels will be examined before and after surgery and compared between those who had gastric bypass or gastric sleeve versus lap banding and the non-surgery control group.
Interventions
- OTHER Oral Alcohol challenge test Alcohol visit first
- OTHER Oral Alcohol challenge test Placebo visit first
- OTHER Intravenous Alcohol Challenge Test (Clamp)
- OTHER Intravenous Alcohol Self-administration Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-03 |
| Est. Completion | 2022-05-25 |
Why NCT02766322 stopped before completion
NCT02766322 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Oral Alcohol challenge test Alcohol visit first is the first listed.
NCT02766322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02766322 about?
NCT02766322 is a clinical study titled "Alcohol and Bariatric Surgery". The investigators wish to study the effects of alcohol on three forms of bariatric surgery, Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG) and laparoscopic adjustable gastric banding (LAGB) and compare them with a non-surgical group. The surgery is not part of the clinical trial. If insura...
What is the current status of trial NCT02766322?
This trial is currently terminated. The enrollment target is 54 participants. The study started on 2016-03. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT02766322?
The interventions under investigation include: Oral Alcohol challenge test Alcohol visit first (OTHER), Oral Alcohol challenge test Placebo visit first (OTHER), Intravenous Alcohol Challenge Test (Clamp) (OTHER), Intravenous Alcohol Self-administration Test (OTHER).
Who is sponsoring clinical trial NCT02766322?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia